Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>The aim of this study was to evaluate the efficacy of postoperative radiotherapy (PORT) in stage pIIIA‐N2 non‐small cell lung cancer (NSCLC) patients with positive surgical margins.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Between January 2003 and December 2015, patients who had undergone lobectomy or pneumonectomy plus mediastinal lymph node dissection or systematic sampling in our single institution were retrospectively reviewed. Those with pIIIA‐N2 NSCLC and positive surgical margins were enrolled into the study. The Kaplan‐Meier method was used for survival analysis, and the log‐rank test was used to analyze differences between the groups. Univariate and multivariate analyses using Cox proportional hazards regression models were performed to evaluate potential prognostic factors for OS. Statistically significant difference was set as <i>P</i> < 0.05. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Of all the 1547 patients with pIIIA‐N2 NSCLC reviewed, 113 patients had positive surgical margins, including 76 patients with R1 resection and 37 with R2 resection. The median overall survival (OS) was 28.3 months in the PORT group and 22.6 months in the non‐PORT group (<i>P</i> = 0.568). Subset analysis showed that for patients with R1 resection, the median OS was 52.4 months in the PORT group which was nonsignificantly longer than that of 22.6 months in the non‐PORT group (<i>P</i> = 0.127), whereas PORT combined with chemotherapy could significantly improve OS, with a median OS of 52.4 months versus 17.2 months (<i>P</i> = 0.027). For patients with R2 resection, PORT made no significant difference in OS (17.6 vs. 63.8 months, <i>P</i> = 0.529). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>For pIIIA‐N2 NSCLC patients with positive surgical margins, PORT did not improve OS, but OS was improved in those patients who underwent R1 resection combined with chemotherapy.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key points</h3></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Significant findings of the study</h3><p>Significant findings of the study: Postoperative radiotherapy (PORT) has been recommended to treat patients with positive surgical margins. However, the existing evidence is controversial and high‐level evidence is lacking.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> What this study adds</h3><p>What this study adds: The PORT group had markedly, but not statistically significant, longer median OS compared with the non‐PORT group in patients with R1 resection. OS was significantly longer in the patients with R1 resection receiving adjuvant CRT than the surgery alone group.</p></section>

The efficacy of postoperative radiotherapy in resected pⅢA-N2 EGFR mutant and wild-type lung adenocarcinoma

Postoperative Radiotherapy Can Improve the Disease-Free Survival of EGFR Wild Type Patients with Pn2 NSCLC after Complete Resection and Adjuvant Chemotherapy

FP01.02 the Efficacy of Postoperative Radiotherapy in IIIA-N2 Non-Squamous NSCLC with Different EGFR Mutation Status: A Retrospective Analysis

Distinct efficacy of postoperative radiotherapy in patients with resected pathological Stage IIIA-N2 lung squamous cell carcinoma

Postoperative Radiotherapy for Patients with Completely Resected Pathological Stage IIIA-N2 Non-Small Cell Lung Cancer: a Preferential Benefit for Squamous Cell Carcinoma

Association Between Clinicopathological Factors and Postoperative Radiotherapy in Patients with Completely Resected Pathological N2 Non-Small Cell Lung Cancer.

Evaluation of Postoperative Radiotherapy Effect on Survival of Resected Stage III-N2 Non-small Cell Lung Cancer Patients

Is Postoperative Radiotherapy Effective in Patients with Completely Resected Pathologic Stage IIIA(N2) Non-Small Cell Lung Cancer? High-risk Populations Should Consider It

Beneficial effects of postoperative radiotherapy for IIIA‑N2 non‑small cell lung cancer after radical resection analysed using the propensity score‑matching method

The Role of Postoperative Radiotherapy on Stage N2 Non-small Cell Lung Cancer

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy

Value of postoperative radiotherapy for stage IIIa-N2 non-small cell lung cancer: an analysis based on SEER database

The Lymph Node Status and Histologic Subtypes Influenced the Effect of Postoperative Radiotherapy on Patients with N2 Positive IIIA Non-Small Cell Lung Cancer

Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer

Postoperative radiotherapy improves survival of patients with ypN2 non-small cell lung cancer after neoadjuvant chemotherapy followed by surgery - A propensity score matching study of the Surveillance, Epidemiology, and End Results database

P1.15-17 Risk Factors of Local Recurrence in EGFR-Mutant Stage III-pN2 Adenocarcinoma after Complete Resection: A Multi-Center Real-World Cohort Study

Postoperative Radiotherapy for Resected Stage IIIA-N2 Non-small-cell Lung Cancer: A Population-Based Time-Trend Study

Validation of the Role of Postoperative Radiotherapy in Improving Disease-Free Survival of Patients with Stage III Ypn2 Non-Small Cell Lung Cancer after Neoadjuvant Therapy Followed by Complete Resection – A Propensity-Score Matching Study

Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: A single-center, retrospective study

The impact of postoperative radiotherapy on the survival of patients with stage III non-small cell lung cancer: A CONSORT-compliant analysis using the SEER database

Postoperative radiotherapy for pathological stage IIIA‐N2 non‐small cell lung cancer with positive surgical margins